Global Medical Communications GMC

Immunotherapy drugs are promising new weapons in the fight against cancer, but they are so strong that they can be toxic to the rest of the human body. The basic idea behind immunotherapy drugs is simple.

Doctors inject special kinds of drugs, especially proteins such as antibodies and cytokines prepared or modified in a lab, into a patient, where they activate the patient's immune cells—T-cells, NK cells, and so on—and help these cells fight the tumor.

In short, immunotherapy drugs work like a powerful cocktail that boosts a patient's own immune system.

Ref: https://bit.ly/3hVNNLo

Previous models assumed that only large droplets pose a relevant risk of infection because small droplets evaporate quickly. At TU Wien (Vienna), however, in cooperation with the University of Padova, it has now been shown that this is not true: Due to the high humidity of the air we breathe, even small droplets can remain in the air much longer than previously assumed. The study was published in the scientific journal PNAS.

Ref: https://bit.ly/39qeHGL

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care, trastuzumab emtansine (T-DM1).

Ref: https://bit.ly/3hYb2Vs